LEFKOWITZ E 2011 Evidence for separation of

HCV subtype 1a into two distinct clades. J Viral Hepat 18:608-618.

109. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941. 110. Ploss A, Dubuisson J.

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012;61(Suppl 1):i25-i35.

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3021 111. Ploss A, Evans MJ,

Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-886.

112. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.

113. Popescu CI, Rouille Y, Dubuisson J. Hepatitis C virus assembly imaging. Viruses 2011;3:2238-2254. 114. PROCTER JB, THOMPSON J, LETUNIC I, CREEVEY C, JOSSINET F, BARTON GJ. 2010. Visualization of multiple alignments phylogenies and

gene family evolution. Nature Methods 7:S16-25.

115. QIU P, CAI XY, DING W, ZHANG Q, NORRIS ED, GREENE JR. 2009. HCV genotyping using statistical classification approach. J Biomed Sci 16:62.

116. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.

117. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, et al. Three- dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 2012;8:e1003056.

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3022 118. Rosa D, Campagnoli S,

Moretto C, Guenzi E, Cousens L, Chin M, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996;93:1759-1763.

119. ROSS RS, VERBEECK J, VIAZOV S, LEMEY P, RANST MV, ROGGENDORF M. 2008. Evidence for a complex mosaic genome pattern in a fulllength hepatitis C virus sequence. Evolutionary Bioinformatics 4:249-254. 120. Sainz B Jr, Barretto N,

Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann- Pick C1-like 1 cholesterol absorption receptor as a new

hepatitis C virus entry factor. Nat Med 2012;18:281-285. 121. Scarselli E, Ansuini H,

Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017- 5025.

122. Sharma NR, Mateu G, Dreux M, Grakoui A, Cosset FL, Melikyan GB. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem 2011;286:30361-30376.

123. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-973.

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3023 124. SWOFFORD D. 2003.

PAUP. Phylogenetic analysis using parsimony (version 4). Sunderland, Massachusetts: Sinauer Associates.

125. TAMURA K, DUDLEY J, NEI M, KUMAR S. 2007. Molecular evolutionary genetics analysis software version 4.0 Mol Biol Evol 24:1596-1599. 126. TAMURA K, PETERSON D, PETERSON N, STECHER G, NEI M, KUMAR S. 2011. MEGA5: Molecular evolutionary genetics analysis using

maximum likelihood,

evolutionary distance and maximum parsimony methods. Mol Biol Evol 28:2731-2739.

127. Targett-Adams P,

Boulant S, Douglas MW, McLauchlan J. Lipid

metabolism and HCV infection. Viruses 2010;2:1195-1217. 128. Targett-Adams P, Hope

G, Boulant S, McLauchlan J. Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production. J Biol Chem 2008;283:16850-16859.

129. TEUFEL A, KRUPP M, WEINMANN A, GALLE PR. 2006. Current bioinformatics tools in genomic biomedical research. Int J Mol Med 17:967-973.

130. Trotard M, Lepere- Douard C, Regeard M, Piquet- Pellorce C, Lavillette D, Cosset FL, et al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J 2009;23:3780-3789. 131. Tscherne DM, Jones CT,

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3024 McKeating JA, Rice CM.

Time- and temperature- dependent activation of hepatitis C virus for low-pH- triggered entry. J Virol 2006;80:1734-1741.

132. UTAMA A, TANIA NP, DHENNI R, GANI RA, HASAN I, SANITYOSO A,

LELOSUTAN S,

MARTAMALA R, LESMANA LA, SULAIMAN A, TAI S. 2010. Genotype diversity of hepatitis C virus in HCV associated liver disease patients in Indonesia. Liver Int 30:1152- 11601. 133. VERBEECK J, STANLEY M, SHIEH J, CELIS L, HUYCK E, WOLLANTS E, MORIMOTO J, FARRIOR A, SABLON E, JANKOWSKI-HENNIG M, SCHAPER C, JOHNSON P,

VAN RANST M, VAN

BRUSSEL M. 2008.

Evaluation of Versant HCV genotype assay (LiPA) 2.0. J Clin Microbiol 46:1901-1906.

134. VERMA V,

CHAKRAVARTI A. 2008. Comparison of 5’non coding core with 5’non-coding regions

of HCV by RT-PCR:

Importance and clinical implications. Curr Microbiol 57:206-211.

135. VINCZE T, POSFAI J, ROBERT R. 2003. NEBcutter: A program to cleave DNA with restriction enzymes. Nucleic Acids Res 31:3688-3691.

136. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3025 Gastroenterology

2007;132:667-678.

137. Wang C, Le SY, Ali N, Siddiqui A. An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5’ noncoding region. RNA 1995;1:526-537.

138. Weiner AJ,

Christopherson C, Hall JE, Bonino F, Saracco G, Brunetto MR, et al. Sequence variation in hepatitis C viral isolates. J Hepatol 1991;13(Suppl 4):S6- S14. 139. Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine

resistance in vitro. J Virol 2008;82:5269-5278.

140. ZEIN N. 2000. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223-235.

141. ZHENG X, PANG M, CHAN A, ROBERTO A,

WARNER D, YEN-

LIEBERMAN B. 2003. Direct comparison of hepatitis C virus genotypes tested by INNO- LiPA HCV II and TruGene HCV genotyping methods. J Clin Virol 28:214-216.

142. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis 2012;205:656-662.

Available online: https://edupediapublications.org/journals/index.php/IJR/ P a g e | 3026 143. Zibert A, Kraas W,

Meisel H, Jung G, Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997;71:4123- 4127.